Revvity RVTY Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Segment revenue by Business | |||||
| Diagnostics | $1.42B+5.1% | $1.36B+5.0% | $1.29B-36.0% | $2.02B— | |
| Life Sciences | $1.43B+2.3% | $1.4B-4.1% | $1.46B+12.8% | $1.29B— | |
| Segment Cost of Revenue by Business | |||||
| Diagnostics | $633.77M+10.0% | $576.37M+5.1% | $548.61M-22.7% | $710.04M— | |
| Life Sciences | $516.3M+5.8% | $488.19M-4.4% | $510.45M+21.9% | $418.83M— | |
| Segment operating income by Business | |||||
| Diagnostics | $344.17M-2.8% | $353.94M+18.8% | $298.03M-61.8% | $781.17M— | |
| Life Sciences | $458.26M-1.9% | $467.28M-8.8% | $512.25M+1.8% | $503.24M— | |
| Segment research and development expenses by Business | |||||
| Diagnostics | $103.58M+15.1% | $90M-13.9% | $104.59M-18.4% | $128.16M— | |
| Life Sciences | $112.03M+7.3% | $104.38M-2.8% | $107.43M+22.3% | $87.86M— | |
| Segment Selling, general and administrative expenses by Business | |||||
| Diagnostics | $343.43M+2.2% | $336.12M-1.5% | $341.16M-14.6% | $399.55M— | |
| Life Sciences | $344.52M+1.7% | $338.76M+3.3% | $328.07M+15.9% | $282.98M— | |
| Foreign currency translation by Business | |||||
| Diagnostics | $48.65M— | —— | —— | —— | |
| Life Sciences | $115.58M+349% | -$46.47M-228% | $36.36M+137% | -$98.27M— | |
| Goodwill by Business | |||||
| Diagnostics | $7.73B— | —— | —— | —— | |
| Life Sciences | $18.61B— | —— | —— | —— | |
| Depreciation by Business | |||||
| Diagnostics | $33.4M-7.4% | $36.07M+6.1% | $33.99M+13.5% | $29.94M— | |
| Life Sciences | $33.49M+11.1% | $30.13M+0.1% | $30.11M+22.8% | $24.51M— | |
| Lease Abandonment Charges Included In Restructuring and Other Costs by Business | |||||
| Diagnostics | $800K— | —— | —— | —— | |
| Life Sciences | $6.2M— | —— | —— | —— | |
| Segment revenue by Geography | |||||
| Americas | $1.26B+2.7% | $1.22B+0.6% | $1.22B-26.9% | $1.66B-17.4% | |
| Asia | $775.11M-1.8% | $789.33M+0.2% | $787.94M-3.6% | $817.37M-19.3% | |
| CHINA | $425.06M-5.5% | $450.01M-1.0% | $454.43M-4.6% | $476.37M+6.0% | |
| Europe | $824.98M+11.1% | $742.61M-0.6% | $747.02M-10.2% | $831.81M-40.5% | |
| GERMANY | $177.66M+9.3% | $162.58M-15.8% | $193.17M— | —— | |
| UNITED KINGDOM | $126.85M+12.4% | $112.88M-10.0% | $125.42M-7.8% | $136.02M-62.0% | |
| UNITED STATES | $1.13B+2.6% | $1.1B-1.8% | $1.12B-27.7% | $1.55B-8.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Revvity break its business down?
- Revvity (RVTY) reports segment revenue by business across 2 parts — Diagnostics and Life Sciences. Each is extracted from the segment footnotes and tracked over time.
- Where does Revvity's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Revvity's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
